This dual-phase regulation may explain the clinical observation of psoriasis patients developing type 2 diabetes, as persistently elevated IL-1β levels are characteristic of psoriatic inflammation [39, 40]. This evidence concerns the gene IL1B and type 2 diabetes mellitus.